ArriVent BioPharma, Inc. (AVBP) · Oct 6, 2026 · Other events
Below the bar — Primary PFS endpoint not met by blinded independent review
ArriVent’s FURVENT clinical trial missed its primary PFS endpoint, putting its lead lung-cancer drug’s development path under review.
ArriVent is a clinical-stage oncology biotech built around firmonertinib, with the company trying to establish the drug in first-line lung cancer while expanding into antibody-drug conjugates. Before this filing, FURVENT was the key near-term value inflection: topline data were expected in the second half of 2026, and the company’s broader plan still depended heavily on firmonertinib’s two global Phase 3 programs.
The pivotal trial failed its core test. FURVENT did not meet its primary endpoint of progression-free survival by blinded independent central review, the prespecified standard intended to determine whether firmonertinib beat platinum-based chemotherapy. 〔0〕 That places the result below the trial’s success bar, regardless of favorable signals in investigator-assessed PFS, response rate, or an immature overall-survival trend.
The filing’s positive secondary signals do not repair the main miss. Management explicitly says the study did not show a meaningful PFS improvement over chemotherapy by BICR, which is the cleanest read on the result. 〔1〕 The secondary-endpoint benefits may preserve questions around subgroups or later analyses, but they do not establish the first-line efficacy claim the Phase 3 trial was designed to prove.
Safety was acceptable, but not enough to offset the efficacy failure. Severe treatment-emergent adverse events were broadly similar across the arms, while severe treatment-related events were numerically lower with firmonertinib than chemotherapy. The filing reports no new safety signal, but a tolerable profile cannot by itself support approval when the primary efficacy endpoint failed. 〔2〕
| Filing metric | Firmonertinib 240 mg | Firmonertinib 160 mg | Control arm |
|---|---|---|---|
| Grade ≥3 treatment-emergent adverse events (Safety data) | 52% | 53% | 55% |
| Grade ≥3 treatment-related adverse events (Safety data) | 26% | 22% | 40% |
The company now has to reassess its lead-program strategy. ArriVent says it is reviewing the full FURVENT dataset and deciding the most appropriate development path for firmonertinib. The drug’s other major clinical opportunity, the ALPACCA Phase 3 study in first-line PACC-mutant NSCLC, remains active, but this failure weakens the broader thesis that firmonertinib can become a differentiated first-line treatment across uncommon EGFR mutations. The company had reported $373.1 million of cash and investments as of June 30, 2026, expected to fund operations into 2028, so the immediate issue is program credibility and development scope rather than an obvious near-term financing need.
Bottom line: This is a material setback to ArriVent’s central drug thesis, not a routine data update. Secondary signals and clean safety may justify further analysis, but the failed independent-review PFS endpoint leaves firmonertinib’s first-line FURVENT path substantially impaired.
Full FURVENT dataset review and development-path decision
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!